医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Japan’s Agency for Medical Research and Development, AMED, Selects Certara’s Phoenix WinNonlin Software to Assess New Drug Candidates

2015年10月20日 PM09:00
このエントリーをはてなブックマークに追加


 

PRINCETON, N.J.

Certara®, the global biosimulation technology-enabled drug development company, today announced that Japan’s new Agency for Medical Research and Development (AMED) has selected Certara’s Phoenix® WinNonlin® software for pharmacokinetic/pharmacodynamic (PK/PD) modeling and non-compartmental analysis of new drug candidates. AMED was launched on April 1, 2015 and fulfills a similar role to the National Institutes of Health in the United States.

“Considered the gold standard for PK/PD and non-compartmental analysis, Phoenix WinNonlin is being used by more than 6,500 researchers at more than 1,500 biopharm companies, academic institutions and global regulatory agencies,” said Certara Chief Executive Officer Edmundo Muniz, MD, PhD. “In fact, Phoenix WinNonlin is relied upon by 100 percent of leading pharma companies, according to survey results published in the January 2015 IQ Consortia report on preclinical PK/PD modeling. We are delighted that AMED chose to start working with Certara right away as the Agency expands its drug development analysis capabilities.”

Prime Minister Shinzo Abe is counting on AMED to move drugs from the bench into the clinic and onto the market. AMED is expected to employ Phoenix WinNonlin to create PK profiles, and assess bioavailability for new drug candidates in its preclinical program. These data will help AMED’s domestic and international biopharmaceutical partners to identify which molecules hold the most therapeutic potential and should be progressed into clinical trials. AMED is currently testing about 200,000 samples provided by 10 biopharmaceutical companies. However, it plans to open the program to additional biopharmaceutical partners shortly. Its initial focus is on the development of drugs for cancer and infectious diseases. AMED will flag promising molecules for its partners and request that they develop them further.

Phoenix WinNonlin is the trusted, long-time industry standard software tool for PK/PD modeling, non-compartmental and compartmental analysis. It is easily validated, delivering accurate, reproducible and traceable results. WinNonlin has powerful graphics, an extensive model library, and its results can readily be shared in a single file with collaborators. It can also perform a bioequivalence analysis, or create a simulation of multiple doses, from single-dose data.

About Certara

Certara is a global biosimulation technology-enabled drug development company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable superior drug development and regulatory decision-making through biosimulation, thus increasing R&D productivity and commercial value. For more information, visit www.certara.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151020005164/en/

CONTACT

Certara Contact:
Ellen Leinfuss, 609-216-9586
Chief
Marketing Officer
or
Media Contact:
Rana
Healthcare Solutions
Lisa Osborne, 206-992-5245
lisa@ranahealth.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明
  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結